Effect of dexmetetomidine during the perioperative period on the postoperative pain of patients after open resection of liver cancer

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100043881

Enrollment

Unknown

Registered

2021-03-04

Start date

2021-03-01

Completion date

Unknown

Last updated

2021-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative pain

Interventions

1:Intraoperative management: dexmedetomidine loading dose of 0.125ug/kg, maintenance dose of 0.075ug/kg.h, PCIA: dexmedetomidine 90mg+ oxycodone 60mg

2:Intraoperative management: dexmedetomidine loading dose of 0.25ug/kg, maintenance dose of 0.15ug/kg.h, PCIA: dexmedetomidine 180mg+ oxycodone 60mg

3:Intraoperative management: dexmedetomidine loading dose of 0.5ug/kg, maintenance dose of 0.3ug/kg.h, PCIA: dexmedetomidine 360mg+ oxycodone 60mg

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Aged 18-70 years; ASA I-II; Dignosed liver cancer with CT; Child-Pugh A.

Exclusion criteria

Exclusion criteria: Severe liver or renal insufficency; cardiovascular disease; allergy to any of the drugs like midazolam, opiods and dexmedetomidine; sedative and analgesic drugs abuse; with a history of asthma; comminication difficulties.

Design outcomes

Secondary

Measure	Time frame
LOS;Postoperative renal function;perioperative remifentanil consumption;perioperative propofol consumption;	—

Primary

Measure	Time frame
Postoperative pain scores;Postoperative oxycodone consumption;	—

Countries

China

Contacts

Public ContactXiaopeng Liu

Beijing Youan Hospital, Capital Medical University

08liuxiaopeng@163.com+86 18710083633

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026